Ana Sayfa
Piyasalar
Grafikler ve Fikirler
Algo
Haberler
Store
Aracı Kurumlar
İndir
Ekonomik Takvim
Alım-Satım Sinyalleri
Web Terminali
Heatmap
Arama yapmak için
/
tuşuna basın: @kullanıcı, $sembol, ...
Ara
Giriş yap
Hesap oluştur
Türkçe
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
KROS
#3564
Keros Therapeutics, Inc. Common Stock
11.550
0
USD
+3.59%
Sektör:
Sağlık Hizmetleri
Baz:
USD
Kar Para Birimi:
USD
Günlük Aralık
Yıllık Aralık
Günlük Değişim
+3.59%
Aylık Değişim
+4.52%
6 aylık değişim
-23.51%
Yıllık Değişim
-23.51%
Önceki Kapanış
11.150
0
Open
11.550
0
Bid
Ask
Low
11.550
0
High
11.550
0
Hacim
54
Piyasalar
ABD Borsası
Sağlık Hizmetleri
KROS
Open full chart
Financials
Overview
Rapor
Statistics
Quarterly
Annual
Value
2020
2021
2022
2023
2024
2025
TTM
Key stats
Total common shares outstanding
23.27 M
24 M
28.54 M
35.98 M
40.56 M
19.72 M
—
Valuation ratios
Enterprise value
1.38 B
1.17 B
1.03 B
1.22 B
82.17 M
114.03 M
-552.13 M
Price to earnings ratio
—
-23.22
-11.08
-8.29
-3.17
8.85
0.84
Price to sales ratio
—
67.92
—
8 410.96
166.94
3.16
10.08
Price to cash flow ratio
—
-21.97
-16.56
-10.2
-3.68
7.17
39.36
Price to book ratio
—
5.61
4.18
3.82
1.04
2.54
3.16
Enterprise value to EBITDA ratio
-29.66
-20.97
-9.05
-7.22
-0.39
1.66
-60.71
Profitability ratios
Return on assets %
-0.17
-0.23
-0.34
-0.41
-0.3
0.26
0.07
Return on equity %
-0.17
-0.24
-0.38
-0.46
-0.33
0.29
0.07
Return on invested capital %
-8 687.99
-2 853.47
-2 576.22
-3 010.6
-3 115.77
811.36
762.3
Gross margin %
—
100
—
100
100
100
400
Operating margin %
—
-280.46
—
-112.54 K
-5 938.96
27.71
-7 958.72
EBITDA margin %
—
-278.58
—
-112 K
-5 904.34
28.25
-7 850.78
Net margin %
—
-292.26
—
-101.32 K
-5 277.55
35.68
-6 324.16
Liquidity ratios
Quick ratio
—
—
—
—
—
—
—
Current ratio
37.27
21.23
17.27
14.25
21.45
15.45
85.71
Inventory turnover
—
—
—
—
—
—
—
Asset turnover
0
0.08
0
0
0.01
0.51
0.34
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
—
—
—
Long term debt to total equity ratio
—
—
—
—
—
—
—
Per share metrics
Operating cash flow per share
—
-2.66
-2.78
-4.23
-4.3
2.84
2.56
EBIT per share
—
-2.42
-4.55
-5.77
-5.63
1.78
1.57
EBITDA per share
—
-2.4
-4.52
-5.74
-5.6
1.82
1.61
Total debt per share
—
—
—
—
—
—
—
Cash per share
—
9.86
11.06
11.25
14.96
7.59
59.22
Net current asset value per share
—
10.78
11.32
11.79
15.73
8.33
62.6
Tangible book value per share
—
10.42
10.99
11.28
15.27
8.01
60.5
Working capital per share
—
10.27
10.67
10.97
15
7.79
59.65
Book value per share
—
10.42
10.99
11.28
15.27
8.01
60.5
Haberler
Insmed (INSM) Soars 5.5%: Is Further Upside Left in the Stock?
KROS: Is the Discount Book Value a Value Trap?
KROS Stock: What to Know About Rinvatercept in DMD
KROS Pipeline Catalysts: DMD Phase II and ALS Plans for 2026
Can Keros Therapeutics Rinvatercept Stand Out in the DMD Market?
Can Reblozyl Stabilize BMY's Top Line Amid Legacy Drugs Decline?
Keros Therapeutics, Inc. (KROS) Reports Q4 Loss, Misses Revenue Estimates
Keros kazancı $0,16 ile beklentilere göre daha kötü, kâr ise beklentilere göre düşük
Keros earnings missed by $0.16, revenue fell short of estimates
Keros Therapeutics eski Lyell CFO’sunu yönetim kuruluna aldı
Should Investors Buy, Sell or Hold KROS Stock Ahead of Q4 Earnings?
Will Reblozyl Shine in Bristol Myers' Fourth-Quarter Results?